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ABSTRACT 
End stage liver disease is the only one of the top five causes of death in the United Kingdom 
still increasing in prevalence year on year. Whilst disease specific treatments have shown 
promise in delaying progression to end stage liver disease, the only curative treatment once 
end stage liver disease has developed is liver transplantation.  There are many causes of end 
stage liver disease but autoimmune disease remains a prevalent but poorly understood with 
limited treatment options to prevent progression to cirrhosis.  Mesenchymal stem cells (MSC) 
are a novel therapeutic strategy which is gaining an evidence base in many conditions 
involving the immune system.  This study describes a technique for the prospective isolation 
of MSC using PDGFRα and Sca-1 (PαS MSC) and following culture expansion these cells are 
administered in a pilot in vitro study using MSC in the OVA-Bil model of autoimmune liver 
disease, with the hypothesis that MSC will reduce liver inflammation in the OVA-Bil mouse 
model. 
 
Male 8-12 week old OVA-Bil mice were injected IP with 1x107 OT1 cells and 4x106 OT2 
cells. Control mice (n=3) were given phosphate buffered saline (PBS) whilst treated mice 
(n=3) were infused with 5x105 PαS MSC via the tail vein on days 3 and 6.  At day 10 mice 
were  and serum alanine transaminase (ALT) and alkaline phosphatase (ALP) analysed. 
Liver tissue was fixed and paraffin sections were stained for Haematoxylin and Eosin (H&E). 
 
Whilst no significant difference was shown in serum markers of liver injury between control 
and MSC treated groups, there was a trend towards a significant reduction in the treated mice 
in both ALT and ALP.  Qualitative analysis of H&E sections demonstrated no difference in 
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lymphocytic infiltration in the portal regions of the liver tissue between the control and MSC 
treated mice. 
 
This work has demonstrated the feasibility of an in vivo animal model of autoimmune 
hepatitis and will guide further study into efficacy and mechanism of action of PαS MSC in 
models of autoimmune liver disease. 
  
IV 
 
DEDICATION 
This thesis is dedicated to my wife Molly, and daughter Florence, for their unwavering 
support in my academic pursuits, and to my parents, for supporting me through my studies 
and career. 
  
V 
 
ACKNOWLEDGEMENTS 
I would like to thank my academic supervisor Professor Bion, for his support and mentorship 
over the past few years and during my academic clinical fellowship.  I would also like to 
thank my laboratory supervisor Professor Newsome, for welcoming me into his laboratory 
and providing me with an environment to learn and research the techniques described here, 
and ultimately gain funding for a PhD to continue this work. 
 
I would like to thank Shankar Suresh, who has taught me a great deal over the last two years 
and supported my constant question asking with mostly helpful answers.  I would also like to 
thank Diarmaid Houlihan for his help in learning to isolate MSC.  I am grateful to Laurence 
Hopkins for teaching me immunohistochemistry, his way. 
 
Finally I would like to thank all of the members of the Liver Laboratories for their support 
and assistance during my research weeks. 
  
VI 
 
CONTENTS 
 
ABSTRACT ................................................................................................................................... II 
DEDICATION ............................................................................................................................... IV 
ACKNOWLEDGEMENTS............................................................................................................... V 
LIST OF ILLUSTRATIONS ........................................................................................................... VIII 
LIST OF TABLES .......................................................................................................................... IX 
LIST OF ABBREVIATIONS ............................................................................................................. X 
 
1. INTRODUCTION ........................................................................................................ 1 
1.1. End Stage Liver Disease ............................................................................................ 1 
1.2. Autoimmune Mediated Liver Disease ...................................................................... 2 
1.3. Autoimmune Hepatitis ............................................................................................. 4 
1.3.1. Background ........................................................................................................... 4 
1.3.2. Autoimmune Hepatitis Pathophysiology.............................................................. 5 
1.3.3. Therapeutic Strategies .......................................................................................... 5 
1.4. Primary Biliary Cirrhosis ........................................................................................... 6 
1.4.1. Background ........................................................................................................... 6 
1.4.2. Primary Biliary Cirrhosis Pathophysiology ............................................................ 7 
1.4.3. Therapeutic Strategies .......................................................................................... 8 
1.5. Primary Sclerosing Cholangitis ................................................................................. 8 
1.6. The OVA-Bil model of Autoimmune Liver Disease ................................................... 9 
1.7. Mesenchymal Stem Cells ....................................................................................... 10 
1.8. Aims and Hypothesis .............................................................................................. 13 
 
2. METHODS ............................................................................................................... 15 
2.1. Literature Searching Techniques ............................................................................ 15 
2.2. Cell Culture ............................................................................................................. 15 
2.3. Cell Passage ............................................................................................................ 15 
2.4. Prospective Isolation Of Purified Murine PαS Mesenchymal Stem Cells .............. 16 
2.4.1. Animal Husbandry .............................................................................................. 16 
2.4.2. Removal and preparation of long bones ............................................................ 17 
2.4.3. Preparation of Cell Suspension From Bone Paste .............................................. 18 
VII 
 
2.4.4. Red Blood Cell Lysis ............................................................................................ 19 
2.4.5. Fluorescent Staining of PαS Mesenchymal Stem Cells ....................................... 19 
2.4.6. Cell Sorting of PαS Mesenchymal Stem Cells ..................................................... 22 
2.5. Growth Factor Priming of PαS Mesenchymal Stem Cells ...................................... 23 
2.6. OVA-Bil Mouse Model ............................................................................................ 23 
2.6.1. Animal Husbandry .............................................................................................. 24 
2.6.2. Induction of Liver Injury ..................................................................................... 24 
2.6.3. Genotyping of OVA-Bil Mice ............................................................................... 25 
2.6.3.1. Sample Preparation ........................................................................................ 25 
2.6.3.2. Polymerase Chain Reaction ............................................................................ 26 
2.6.3.3. PCR Gel Preparation ........................................................................................ 27 
2.6.3.4. PCR Gel Electrophoresis .................................................................................. 28 
2.6.4. Use of PαS Mesenchymal Stem Cells in OVA-Bil Model ..................................... 28 
2.6.5. Immunohistochemistry and Staining of Murine Solid Organs ........................... 29 
 
3. RESULTS .................................................................................................................. 30 
3.1. Cell sorting of PαS Mesenchymal Stem Cells ......................................................... 30 
3.2. Gel Electrophoresis of PCR of OVA-Bil DNA ........................................................... 31 
3.3. Liver Damage using the OVA-Bil Mouse Model ..................................................... 32 
3.4. Effect of PαS Cells on Injured and Uninjured Mice ................................................ 34 
 
4. DISCUSSION ............................................................................................................ 37 
4.1. Limitations of the Experimental Techniques ......................................................... 37 
4.2. Purified PαS Mesenchymal Stem Cells ................................................................... 38 
4.3. OVA-Bil Mouse Model of Autoimmune Liver Disease ........................................... 39 
4.4. Mesenchymal Stem Cells In Autoimmune Disease ................................................ 40 
4.5. Mechanisms Of Mesenchymal Stem Cell Immunosuppression ............................. 42 
4.6. Localisation of Mesenchymal Stem Cells During Immunosuppression ................. 44 
4.7. Future Uses of Mesenchymal Stem Cells ............................................................... 46 
 
5. CONCLUSIONS ........................................................................................................ 48 
 
LIST OF REFERENCES ................................................................................................................. 49 
 
VIII 
 
LIST OF ILLUSTRATIONS 
Figure 1 A photograph depicting the MoFlo
TM
 XDP Cell Sorter setup at the University of 
Birmingham .............................................................................................................................. 22 
Figure 2 Representative scatter plots demonstrating the gating strategy used during cell 
sorting of long bone derived cells suspension ......................................................................... 30 
Figure 3 PCR genotyping of OVA-Bil and OT 1 mice using a HotStart Taq polymerase and gel 
electrophoresis ......................................................................................................................... 31 
Figure 4 H&E Stained sections of liver tissue from injured OVA-Bil Mice at day 10 post 
adoptive transfer of 1x10
7
 OT1 cells and 4x10
6
 OT2 cells demonstrating lymphocytic 
infiltration into the biliary cells encasing the portal tracts. ..................................................... 33 
Figure 5 Serum ALT and ALP Levels Day 10 following adoptive transfer of 1x10
7
 OT1 cells and 
4x10
6
 OT2 cells in OVA-Bil mice treated with PαS MSC demonstrate non-significant 
decreases .................................................................................................................................. 35 
Figure 6 Liver histology of treated and untreated OVA-Bil livers day 10 post adoptive transfer 
of 1x10
7
 OT1 cells and 4x10
6
 OT2 cells ..................................................................................... 36 
Figure 7 Demonstration images using CryoViz
TM
 tracking MSC with a fluorescent tag; a) 
whole mouse image, b) organ specific views (Provided by BioInVision) ................................. 45 
 
  
IX 
 
LIST OF TABLES 
Table 1 A list of the most common causes of Liver Cirrhosis ..................................................... 2 
Table 2 A summary of the phenotypic markers of autoimmune liver disease .......................... 3 
Table 3 A Thermocycler protocol for HotStart PCR based on a base pair length of 994. ........ 27 
Table 4 A summary of the common side effects seen in patients taking regular 
corticosteroids .......................................................................................................................... 41 
Table 5 A summary of the inflammatory cytokines modulated by MSC.................................. 43 
 
  
X 
 
LIST OF ABBREVIATIONS 
(In alphabetical order) 
 
α-MEM Alpha Modified Minimum Essential Medium (Eagle) 
aCGH Array Comparative Genomic Hybridization 
AIH Autoimmune Hepatitis 
ALP Alkaline Phosphatase 
ALT Alanine Transaminase 
ANA Anti-Nuclear Antibody 
Anti-LC 1 Anti-Liver Cytosol Type 1 
Anti-LKM 1 Anti-Liver Kidney Microsomal Type 1 
Anti-SMA Anti-Smooth Muscle Antibody 
ASBT Apical Sodium dependent Bile acid Transporters 
AST Aspartate Transaminase 
CFU-F Colony forming unit fibroblast 
DBD Donation after Brainstem Death 
DCD Donation after Cardiac Death 
DMEM Dulbecco's Modified Eagle's Medium 
DNA Deoxyribonucleic Acid 
dNTP Deoxyribonucleotide Triphosphate 
EDTA Ethylenediaminetetraacetic acid 
ESL End stage Liver Disease 
FBS/FCS Foetal Bovine/Calf Serum 
GFP Green Fluorescent Protein 
HBSS Hank's Balanced Salt Solution 
HGF Hepatocyte growth factor 
XI 
 
HLA Human leukocyte antigen  
HO1 Haem Oxygenase 1 
IAIHG International Autoimmune Hepatitis Group 
IDO Indoleamine 2,3-dioxygenase 
IFNγ Interferon gamma 
IGF Insulin like growth factor 
IL Interleukin 
IP Intra-peritoneal 
IV Intravenous 
MHC Major histocompatibility complex 
MSC Mesenchymal Stem/Stromal Cell 
NASH Non alcoholic steato hepatitis 
PBC Primary Biliary Cirrhosis 
PC Personal Computer 
PCR Polymerase Chain Reaction 
PDC Pyruvate dehydrogenase complex 
PGE2 Prostaglandin E2 
PGE2 Prostaglandin E2 
PSC Primary Sclerosing Cholangitis 
PSG Penicillin-Streptomycin-Glutamine 
RNA Ribonucleic Acid 
SC Subcutaneous 
TBE Tris/Borate/EDTA 
Tm Melting Point 
TNFα Tumour necrosis factor alpha 
Tris 2-Amino-2-(hydroxymethyl)-1,3-propanediol 
XII 
 
UC Ulcerative Colitis 
UDCA Ursodeoxycholic acid 
UDCA Ursodeoxycholic acid 
UK United Kingdom 
USA United States of America 
UV Ultra Violet 
 
 
1 
 
 
1. INTRODUCTION 
1.1. End Stage Liver Disease 
End stage Liver disease is currently responsible for 2% of deaths in the United Kingdom and 
is the only important cause of death still continuing to increase, with a rise in incidence of 
20% in 20121.  The only proven curative treatment for end stage liver disease is liver 
transplantation, but with increasing donor waiting lists and the increasing demand due to 
rising prevalence of liver disease other therapeutic strategies are in dire need.  In the UK in 
2012-2013 there were 817 (53% of the total waiting list) patients receiving a liver transplant, 
497 (32%) patients still waiting and 84 (5%) died whilst waiting for a liver transplant.  The 
median number of days from listing to transplantation was 147 over the period 2008-20112.  
The UK Chief Medical Officer recently highlighted end stage liver disease as a preventable 
cause of death which is continuing to increase in prevalence3, with a clear need for new 
treatment options due to the limited number of organs available for transplantation. 
 
There are a number of causes of liver cirrhosis and end-stage liver disease (Table 1).  Whilst 
alcohol related liver disease and chronic hepatitis C infection are among the most common 
autoimmune hepatitis (AIH) and primary biliary cirrhosis (PBC) are important causes of liver 
disease4. 
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Causes of Liver Cirrhosis 
Alcohol related liver disease Primary Biliary Cirrhosis 
Viral Hepatitis B Wilson's Disease 
Viral Hepatitis C 1-antitrypsin deficiency 
Fatty Liver/NASH Budd-Chiari Syndrome 
Haemochromatosis Cystic Fibrosis 
Primary Sclerosing Cholangitis Autoimmune Hepatitis 
Table 1 A list of the most common causes of Liver Cirrhosis 
 
Liver disease is highly prevalent in young adults, and a higher proportion of younger people 
are affected by liver disease than the other major causes of death, leading to a large number of 
life years lost due to the terminal nature of many of the causes.  Clearly novel therapeutic 
strategies are in great demand to reduce the global impact of this group of diseases. 
 
1.2. Autoimmune Mediated Liver Disease 
The concept of the immune system attacking the body is well established.  Waldenström first 
described a series of young women who suffered from a form of fluctuating hepatitis over 50 
years ago5.  This was followed by an important early text that was published by Macaky and 
Burnet describing the process of immune tolerance and the consequences of a failure of the 
tolerance process6.  This early but comprehensive description of autoimmune disease 
discussed approximately 30 known diseases including "Active chronic lupoid hepatitis", now 
known to be autoimmune hepatitis.  In the 1980s AIH was recognised as a distinct entity 
named "Chronic active autoimmune hepatitis"7, the term AIH being coined in the 1990s after 
international meetings in Brighton, UK and Los Angeles, USA8. 
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Whilst the immune system can attack the liver in a number of ways leading to a variety of 
conditions such as Primary Biliary Cirrhosis (PBC) and Primary Sclerosing Cholangitis 
(PSC), the distinction between these conditions is not as well defined as once thought and 
there is almost certainly an overlapping spectrum of autoimmune diseases of the liver9,10. 
Attempts have been made to standardise the definition of these overlapping pathologies by the 
International Autoimmune Hepatitis Group (AIHG)11. 
 
There are phenotypic differences between the main causes of autoimmune liver disease (Table 
2), but these clinical markers are not absolute and may exist to a greater or lesser degree 
further blurring the line between one distinct condition and the others. 
 
 AIH PBC PSC 
Age All age groups >45 years Usually >40 
Gender Female:Male Type 1 
4:1, Type 2 9:1 
Female:Male 9:1 Female:Male 3:7 
ANA 1:40 titre in 70-80% Disease specific ANA 
in 30-50% 
Non-specific ANA in 
70-80% 
Anti-LKM 1 3-4% (categorises as 
type 2 AIH) 
Not present Note present 
pANCA 90% Not present 26-94% 
Interface hepatitis Characteristic Occasionally present Occasionally present 
Response to 
immunosuppression 
Yes No No 
Table 2 A summary of the phenotypic markers of autoimmune liver disease 
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The mechanisms by which liver injury is perpetrated in the 3 main autoimmune liver diseases 
(AIH, PBC and PSC) are not fully understood but appear to have similar aetiologies.  Liver 
damage due to antibody mediated immune activation12,13 and cellular immune activation14,15 
have both been implicated.  Genetic predisposition coupled with environmental factors have 
also been shown to be contributory in all 3 conditions16,17,18,19 leading to a persistent loss of 
immune tolerance and sustained ongoing liver injury by the immune system.  The pattern of 
liver injury in AIH is mainly involving the portal and peri-portal areas, whereas in contrast to 
this, the damage seen in PBC and PSC is mainly found in the biliary epithelial cells.  Patients 
with PBC and PSC are susceptible to hepatocyte injury and hepatic inflammation, but this is 
likely secondary to the biliary damage sustained, although the mechanisms underlying this 
have not been fully elucidated20. 
 
1.3. Autoimmune Hepatitis 
1.3.1. Background 
Autoimmune hepatitis (AIH) is one of the three main types of autoimmune disease which is 
specific to the liver and forms part of the overlap spectrum with PBC and PSC.  AIH is 
characterised by a progressive inflammatory condition within the liver and on histological 
examination interface hepatitis is usually found21.  There is no clear genetic or environmental 
trigger solely responsible for the development of AIH but there are a number of genes that 
have been implicated with the strongest associations being in genes encoding the Human 
Leukocyte Antigen (HLA)22. There are two distinct types of AIH, type 1, which is associated 
with HLA-DR3 and HLA-DR423, and type 2, which is associated with HLA-DR3 and HLA-
DR724.  There is an increased incidence in females compared with males with a female:male 
ratio of 4:1 in type 1 AIH and 9:1 in type 2 AIH.  A key feature of AIH is that it responds 
5 
 
favourably to immunosuppression with prednisolone and azathioprine compared with PBC 
and PSC which generally do not25.  Whilst treatment is often effective overall, 20% of patients 
do not respond to conventional therapy26. 
 
1.3.2. Autoimmune Hepatitis Pathophysiology 
AIH can be sub-classified into two types based on the types of auto-antibodies present in the 
serum; type 1 is defined as positive for Anti-Nuclear Antibody (ANA) and/or Anti-Smooth 
Muscle Antibody Type 1 (Anti-SMA 1), and type 2, defined as positive for Anti-Liver Kidney 
Microsomal Antibody Type 1 (Anti-LKM 1) or Anti Liver Cytosol Antibody Type 1 (Anti-
LC 1)27. 
 
Regulatory T-Cells almost certainly play a role in the pathophysiology of AIH and in 
particular the sub-group expressing the markers CD4, CD25 and FOXP328 
(CD4+CD25+FOXP3+), a type of regulatory T-Cell that has been shown to confer peripheral 
immune tolerance and have a role in the prevention of autoimmune disease29.  These 
regulatory cells can suppress auto antibody production through the release of interleukin-10 
(IL-10) and TGF-β.  It has been shown that at the time of diagnosis both the number and the 
regulatory function of CD25+CD4+ cells is reduced, but increases following the induction of 
remission30. 
 
1.3.3. Therapeutic Strategies 
It has long been recognised that suppression of the immune system leads to a more favourable 
outcome in patients with AIH31.  Current guidelines split treatment of AIH into two distinct 
elements, induction of remission and maintenance of remission.  Induction is achieved with 
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the use of high dose corticosteroids such as prednisolone in combination with the anti-
proliferative immunosuppressant azathioprine, a drug which mainly targets B and T 
lymphocytes.  Once remission is achieved maintenance schedules of either azathioprine alone 
or in combination with low dose prednisolone are used32, although as with many diseases the 
aim is to minimise long term exposure to exogenous corticosteroids due to the significant side 
effect profile.  Other treatment modalities are currently under investigation such as the inosine 
monophosphate dehydrogenase inhibitor mycophenolate mofetil33, but whilst there are some 
modest benefits of other treatment strategies no one optimal medication regime has been 
found to be significantly better than the current treatment recommendations.  There are 
limited numbers of patients with overlap syndromes therefore therapeutic strategies are 
difficult to research clinically but patients with features of AIH should be considered for 
immunosuppressive therapy11.  Liver Transplantation is required in up to 20% of patients, 
either due to a hyper acute presentation not responding to steroids, or due to decompensated 
end stage liver disease34. 
 
1.4. Primary Biliary Cirrhosis 
1.4.1. Background 
Primary Biliary Cirrhosis (PBC) is one of the 3 main autoimmune diseases affecting the liver.  
The aetiology is unclear, however due to its association with other autoimmune disorders it is 
likely that it is also an autoimmune condition and hence why it is considered here.  There are 
no clear genetic factors that have been discovered although up to 6% of patients with PBC 
have an effected family member35. 
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Patients with PBC are often asymptomatic at diagnosis and the finding of a raised serum 
Alkaline Phosphatase (ALP), a hydrolase enzyme used as a marker for cholestasis, may be the 
only indicator36. 
   
1.4.2. Primary Biliary Cirrhosis Pathophysiology 
PBC is characterised by destruction of bile ducts, and involves inflammation and disruption of 
the basement membrane of the bile duct cells37.  The ducts become infiltrated with 
lymphocytes, macrophages and plasma cells which can lead to granuloma formation and cell 
loss occurs via necrosis rather than apoptosis38.  Whilst the specific mechanisms responsible 
for damage to the liver have not been fully elucidated one of the most prevalent auto-
antibodies that has been found is directed against the 2-oxo-acid dehydrogenase group of 
enzymes found in the mitochondria39.  The main immune response effects the pyruvate 
dehydrogenase complex on the E2 binding site (PDC-E2). The continued activation of B-
Cells reactive against PDC-E2 and their subsequent activation by T-Lymphocytes has been 
demonstrated using structurally similar compounds such as lipoic acid, and proposed as a 
mechanism of autoimmune injury in patients with PBC40, however it has recently been 
demonstrated that patients with PBC possess CD4+ T-Cells directed against PDC-E2 whereas 
healthy controls do not41.  CD8+ T-Cells reactive against PDC-E2 have also been shown to be 
found in the livers of patients with PBC42.  It has also been shown that patients with PBC 
have functionally and phenotypically altered CD8+ T regulatory cells43.  Whilst many types of 
immune damage have been proposed it is still not clear the exact mechanism by which PBC 
develops or exerts its effects. 
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1.4.3. Therapeutic Strategies 
Treatment of PBC is with ursodeoxycholic acid (UDCA), and in contrast to AIH there is no 
role for corticosteroids as PBC shows no response, although a small group of overlapping 
syndromes may see some benefit from their use.  Survival is variable with treatment, as is the 
duration of time between diagnosis and development of liver failure.  Approximately 25% of 
patients will develop liver failure within 10 years of diagnosis44.  Liver transplantation is the 
only effective treatment for patients with late stage disease, but following liver transplant up 
to 30% of patients will have a recurrence of the disease45, however this is usually at a 
histological level rather than being clinically significant. 
 
1.5. Primary Sclerosing Cholangitis 
Primary Sclerosing Cholangitis (PSC) is a chronic autoimmune disease predominantly 
affecting the liver.  Characteristic histological changes include inflammation of the biliary tree 
effecting both the intra-hepatic and extra-hepatic regions.  There is a male:female ratio of 2:1 
in contrast to the other autoimmune disorders discussed which have a female preponderance46.  
There is also a strong link with Ulcerative Colitis (UC) with 70% of patients with PSC also 
suffering from UC47.  Currently there is little in the way of treatment options for PSC other 
than liver transplantation with all the risks associated with it.  Whilst there is considerable 
overlap and similarities between AIH, PBC and PSC the differences are sufficient that the 
animal models used in this study do not reflect the pathophysiology of PSC sufficiently well 
and so it will not be considered further. 
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1.6. The OVA-Bil model of Autoimmune Liver Disease 
There are a wealth of animal models that represent different liver diseases.  Models of PBC 
can be separated into spontaneous and induced.  Spontaneous models would be impractical 
for this study due to the limited window but long expansion time required for PαS MSC.  The 
OVA-Bil model was chosen due to familiarity, local availability of the model and following 
review of the literature it was decided that this model closely represented the disease 
processes being studied. 
 
The Ova-Bil mouse model of autoimmune liver injury was developed by Buxbaum48 in 2006 
in order to allow researchers to explore the early immune responses following the recognition 
of antigen on biliary epithelium.  Transgenic mice based on a background C57BL/6 were 
developed by injecting purified DNA constructs into oocytes.  DNA constructs code for apical 
sodium dependant bile acid transporters with ovalbumin bound to their membranes.  The 
ovalbumin is fused with a human transferrin receptor making the TFR-OVA complex specific 
for the biliary epithelium.  Induction of liver injury is achieved following adoptive transfer of 
ovalbumin specific CD8+ (OT 1) and CD4+ (OT2) T-Cells.  Transgenic mice are used to 
produce either OT1 or OT2 cells which are then extracted via splenectomy.  Cells are injected 
into OVA-Bil mice via the intra-peritoneal route. 
 
The extent of liver injury occurring in the OVA-Bil mice is dependent on the number of T-
Cells transferred.  Following adoptive transfer of 5x106 OT1 cells and 2x106 OT2 cells serum 
Alanine transaminase (ALT), an enzyme found in hepatocytes and used as a marker of 
hepatocyte injury, increases to 8 times the baseline level and peaks at day 10, but the greatest 
increase in ALT was following adoptive transfer of 1x107 OT1 cells and 4x106 OT2 cells (an 
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increase of 30 times the baseline).  Serum ALP will double from baseline at the time of peak 
ALT rise.  T-Cell mediated bile duct damage and hepatocellular inflammation and necrosis 
are seen. 
 
The inflammatory response usually terminates after day 11 and ALT begins to decrease.  The 
mechanisms behind this are complex and likely due to exhaustion of transplanted T-Cells.  As 
OVA-Bil mice are tolerant to ovalbumin, adoptive transfer of ovalbumin specific T-Cells is 
required for induction of liver injury and hence this is an induced model rather than a 
spontaneous model. 
 
1.7. Mesenchymal Stem Cells 
There is a lot of controversy in the literature regarding Mesenchymal Stem Cells (MSC), what 
they really are, what their function is and how they can be used clinically.  The term was first 
used in 1991 by Caplan49, although earlier work by Friedenstein demonstrated a plastic 
adherent bone marrow cell termed the colony forming unit fibroblast (CFU-F)50.  These non-
haematopoietic stem cells are multipotent, and have been referred to as skeletal stem cells 
reflecting their differentiation potential51, in other words they are capable of limited 
differentiation into particular cell lines rather than true pluripotency which is seen in 
embryonic stem cells.  MSC have been shown to reside on the outer surface of bone marrow 
sinusoids and form part of the stromal compartment of the bone marrow52, hence their 
alternative name, Mesenchymal Stromal Cells.  Various markers have been suggested in order 
to define MSC, in humans they include; CD146, CD105, ALP, VCAM1 and STRO-153, and 
CD105, CD90 and VCAM1 in mice54.  These markers demonstrate a heterogeneous 
population of cells and further studies have suggested the involvement of CD2, SSEA-1 and 
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SSEA-2 as markers of a hierarchy of MSC differentiation55.  Until recently the isolation of 
MSC involved techniques utilising their plastic adherent properties.  The development of an 
isolation technique for highly purified MSC using the markers PDGFR-α and Sca-1, so called 
PαS cells80,81, has enabled the study of a subgroup of MSC that still retain all of the properties 
that make MSC an important therapeutic tool.  MSC are capable of tri-lineage differentiation 
having the ability to form bone, cartilage and fat56.  Whilst MSC have been thought of as 
stromal cells supporting the haematopoietic cells, their ability to self-renew has been recently 
shown57.  The MSC transcriptome contains a combination of genes which characterise early 
but committed osteogenic cells such as the gene Runx2, as well as genes found in perivascular 
cells58. 
 
A key problem with the current literature is that there is no clear definition that adequately 
describes MSC which can be used clinically due to the non-specific surface markers used in 
their isolation.  A widely accepted definition proposed in a position statement by the 
International Society for Cellular Therapy59, has been argued to be deeply flawed, and the 
loose set of properties described such as the ability to accumulate hydrophobic, mineralised 
and polyanionic material (such as fat, bone and cartilage) are properties that could be ascribed 
to a wide range of connective tissue cells60.  This lack of clarity and specificity regarding the 
definition and subsequent isolation of MSC has clear implications for clinical trials and the 
reproducibility and predictability of results obtained.  There is a clear need for a more specific 
definition of MSC and more selective isolation techniques.  The advantages of a pure, well 
defined cell population likely includes increased potency and karyotypic stability, as key 
concerns levied at the more heterogeneous MSC populations is that of a lack of 
reproducibility in clinical trials, and of malignant transformation61. 
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Tissue regeneration and reprogramming have been the mainstay of research areas for the use 
of MSC.  It has been shown extensively that bone marrow derived MSC, administered into 
damaged tissue, can lead to the generation of new bone and associated tissues by enhancing 
the regenerative properties of cells local to the defect62,63.  These MSC have a potential role in 
reducing local inflammatory cytokines by inhibiting the immune response64.  Whilst the 
theory that MSC may exhibit pluripotency now seems to have little credence, there still 
remains a number of research groups looking into the effect of MSC in other non-skeletal 
tissues and their ability to regenerate these tissues, hypothesising that there are other 
mechanism at play not related to pluripotency65.  There are a number of non-progenitor 
properties of MSC that have recently come to light and are undergoing study.  Anti-
inflammatory and immunoregulatory properties are important effects of MSC with great 
clinical potential, however these effects are not stem cell effects, moreover these properties of 
MSC are much more in keeping with those of fibroblasts to which they have been 
compared66. 
 
The ability MSC to suppress the immune system has gained popularity as a potential 
therapeutic intervention67.  There is still work to be done to ascertain all of the mechanisms by 
which MSC can exert their immunosuppressive effects, but current mechanisms that have 
shown promise are those requiring close cell contact and honing to areas of active 
inflammation.  Mediators responsible for MSC mediated immunosuppression include; TGF-β, 
IDO, PGE2, IGF, IFNγ, IL 10 and TNFα68,69,70,71.  Whilst the bulk of the literature focuses on 
these direct mediators, requiring close cell contact, there has been a suggestion that MSC may 
be able to exert their effect remotely72.  The whole picture with regards to MSC 
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immunosuppression has not been fully elucidated, it is likely that inhibition of T-Cell function 
is key73, however there is growing evidence that MSC can also exert their effect via myeloid 
cell lines such as myeloid derived suppressor cells74.  There are few clinical trials 
investigating the utility of MSC as immunosuppressant therapy, one notable area that has 
been studied is graft versus host disease, and whilst MSC have shown a lot of promise it is 
clear that a number of variables such as timing of infusions may determine whether MSC 
exert an immunosuppressive or pro-inflammatory effect75,76,77.   
 
Route of administration is also an area that requires study.  The pharmacokinetics of MSC are 
not fully understood, but it has been clearly shown that when delivered via the intravenous 
route a large proportion of the cells adhere to the lungs which may cause endothelial cell 
damage78.  However as positive effects at target sites have been shown in vivo using this route 
of administration without significant side effects, it seems that the clinical translation of 
intravenous administration is reasonable if carried out cautiously. 
 
The various proposed effects of MSC, both in the field of regeneration and inflammation 
mean that these cells have a huge potential in many different areas of medicine and types of 
disease process79.  Clearly MSC are a potential therapy for autoimmune disease, and this 
merits further study. 
 
1.8. Aims and Hypothesis 
Isolation of purified PαS MSC is key to enable the investigation of their mechanisms of 
action, as a highly purified cell line will remove the confounders that occur when using more 
heterogeneous cells types.  The first aim of this study is to acquire the ability to consistently 
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perform the complex isolation of purified PαS MSC.  The second aim is to test the ability of 
these PαS MSC to suppress autoimmune mediated liver injury in a mouse model of 
autoimmune liver disease. 
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2. METHODS 
2.1. Literature Searching Techniques 
The literature review for this thesis was carried out using systematic search methodologies.  
Multiple searches were performed for the different sections of this thesis over the period of 
the 7th of July 2014 to the 28th of July 2014.  The following databases were used; Medline, 
EMBASE, Cochrane as well as searching relevant references from papers found and further 
searches using Google Scholar. 
 
2.2. Cell Culture 
Following cell sorting isolated purified PαS MSC were cultured in α-Modified Eagles 
Medium (α-MEM, Invitrogen).  The medium was treated with 1% Penicillin-Streptomycin-
Glutamine (PSG, Invitrogen) with the addition of 10% Foetal Calf Serum/Foetal Bovine 
Serum (FBS, Invitrogen).  Media was changed every 3 days and cells were assessed under 
light microscopy daily.  When cells reached 90% confluencey they were passaged and 
separated into larger containers.  A minimum seeding density of 5x103 cells per cm2 was used. 
 
2.3. Cell Passage 
Cell passage was performed when signs of confluence were detected.  Medium was removed 
and the cells were washed 3 times with Phosphate Buffered Saline (PBS) whilst still adherent 
to the container or plate they were currently housed in.  A combination of trypsin and EDTA 
(TrypLE, Invitrogen) was added to the container and left covered in an incubator at 37°C for 
3 minutes.  Loss of adherence was confirmed by microscopy and then the trypsin mixture was 
neutralised by the addition of an equal volume of the treated α-MEM (with added PSG and 
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FBS).  The cell suspension was transferred by pipette into either a 20ml or 50ml FalconTM 
Conical Centrifuge tube depending on the volume of suspension being separated. Cells were 
spun by centrifuge at 2000rpm for 5 minutes.  The supernatant was discarded and the cells 
were then resuspended by vigorous tapping of the conical tube until a homogenous cell 
suspension remained.  An appropriate volume of medium was then added and the suspension 
agitated to achieve a homogenous mixture.  The cells were then seeded onto larger plates to 
allow for continued growth. 
 
2.4. Prospective Isolation Of Purified Murine PαS Mesenchymal Stem Cells 
The following methodology was developed by Morikawa et al80 and then expanded on by 
Houlihan et al81.  The technique required a number of years of optimisation by my colleagues 
Diarmaid Houlihan and Shankar Suresh in order to be consistent and reproducible in the 
laboratory environment at the University of Birmingham.  The technique allows for the 
isolation of highly purified (99% pure) PαS MSC which so far has not been achieved by any 
other technique.  The learning of this isolation technique has formed a large part of the work I 
have undertaken during my MRes research period and its complexities have meant that other 
students have struggled to reproduce this technique.  As such the methods used in order to 
isolate purified PαS MSC will be described in detail 
 
2.4.1. Animal Husbandry 
Wild type C57BL/6 mice were used from stock maintained at the University of Birmingham. 
All mice were housed in the  and cared for 
using the well established care protocols in that facility. 
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All scientific procedures performed on animals were carried out in accordance with the 
Animals (Scientific Procedures) Act 1986, UK, and all procedures underwent ethical review 
prior to being performed. 
 
2.4.2. Removal and preparation of long bones 
Wildtype mice (C57BL/6) were used aged between 8 and 12 weeks.  Numbers of mice used 
varied depending on stock but usually between 10 and 15 were required in order to achieve a 
suitable yield of PαS MSC.  Mice were  
.  Mice were immediately sprayed with a solution of 70% ethanol.  A transverse 
incision in the lower abdomen/pelvic region was performed to allow access to the leg bones.  
Skin and muscle was retracted using forceps and care was taken not to contaminate the 
working area with hair and faeces.  The skin was retracted over the ankle and an incision 
made through the ankle joint with sharp scissors removing the foot which was discarded.  The 
tibia was exposed using a blunt dissection technique and a further incision through the knee 
joint performed in order to free the tibia.  The bone was then cleaned using tissue paper to 
remove all loosely adherent tissues before placing the clean bone into a container of PBS 
stored on ice.  The hip joint was fixed with forceps and further blunt dissection carried out in 
order to release the femur.  A further incision was then made through the hip joint freeing the 
femur.  This was also cleaned with tissue paper and stored in PBS as described above.  This 
procedure was repeated for both legs on every mouse being used. 
 
Following the surgical stage of the isolation all bones were washed three times by agitating in 
fresh PBS.  The bones were then placed into a sterile mortar and a single break made with a 
pestle by gentle compression at the centre of each bone individually.  Bones were then cut 
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using sharp, sterile scissors into small fragments for approximately 5 minutes until there was 
minimal resistance to cutting from the resulting paste. The bony paste was then washed in 
PBS and the supernatant discarded.  The bone paste were then placed into a 50ml FalconTM 
Conical Centrifuge tube containing 20ml of Dulbecco's Modified Eagles Medium (DMEM, 
Invitrogen) preheated to 37°C with 0.2% collagenase (Wako) and PSG.  The tube was placed 
onto a shaker in an incubator at 37°C with an oscillatory setting of 125rpm for 1 hour. 
 
2.4.3. Preparation of Cell Suspension From Bone Paste 
On removal from the incubator the tube was immediately placed on ice to stop the collagenase 
reaction.  The bone fragments were filtered using a 70µm sterile filter (BD Falcon) into a new 
conical tube and kept on ice.  The remaining bone fragments/bone paste are returned to the 
mortar.  A solution of Hank's Balanced Salt Solution (HBSS) is prepared with the addition of 
2% FBS, 1% PSG and 10mM of HEPES buffer (Sigma).  2.5ml of this HBSS+ solution is 
added to the bone fragments.  The bone fragments were then gently crushed using the pestle 
with repeated light tapping for 100 taps.  This was followed by the addition of a further 2.5ml 
of the HBSS+ solution was added using a pipette.  The total of 5ml of solution was pipetted up 
and down 3 times to aid with cell release.  Gentle swirling of the bone fragments and liquid 
was carried out using the pestle for 30 seconds.  Further mixing with the pipette was carried 
out with repeat up and down transfer.  The solution was then carefully drawn up into the 
pipette being sure to leave the remaining bone fragments and the solution filtered through a 70 
µm filter into the conical tube containing the previous filtrate, remaining on ice at all times.  
This process was repeated a further 5 times until a total of 50ml of solution had been collected 
in the conical tube. 
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The solution was subsequently spun in a pre-chilled centrifuge at 4°C for 7 minutes at 280g 
(1350rpm).  Following centrifugation the supernatant was discarded and the cell pellet 
resuspended as previously described but no medium added. 
 
2.4.4. Red Blood Cell Lysis 
Red blood cell lysis was required in order to remove all of the red blood cells, which are not 
being collected, and therefore improve the efficiency of the later sorting step.  Whilst the 
technique described is a non-standard technique it has been found through meticulous 
optimisation to give the greatest yield of PαS MSC compared with other methods of red cell 
lysis. 
 
The resuspended pellet present in a 50ml conical tube had 1ml of cold (approximately 4°C) 
sterile water (H2O) added whilst continuous rotating of the tube was carried out by hand.  
After 5 seconds of contact with the water 1ml of double strength PBS solution (with 4% FBS 
added)  was added followed by 13ml of HBSS+ solution to make a total volume of 15ml in 
order to quench the reaction.  The cell suspension was then filtered through a sterile 70 µm 
filter before further spinning in a pre-chilled centrifuge at 4°C for 5 minutes at 280g 
(1350rpm).  Following this the supernatant was again discarded and the cell pellet 
resuspended as described previously in 1ml of the HBSS+ solution. 
 
2.4.5. Fluorescent Staining of PαS Mesenchymal Stem Cells 
The staining colours were determined after careful analysis of the requirements of the 
MoFloTM Cell sorter at the University of Birmingham along with the availability of stains for 
the relevant markers.  The antibody panel used was as described in the literature80,81. 
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The antibodies used were as follows; CD45-PE (eBioscience), Ter-119-PE (eBioscience), 
Sca-1-FITC (eBioscience) and PDGFRα-APC (eBioscience).  Propidium Iodide (PI, Sigma) 
solution was also used as described later. 
 
Sterile FACS tubes were used for all samples and controls.  Staining of the main sample was 
carried out in the conical tube and transferred to a cuvette as described later.  All samples 
were kept on ice during the staining process.  Staining was carried out in a standard hood with 
the light switched off and all antibodies were protected from light exposure. 
 
Control tubes were as follows; negative control (cells only), positive control for PE (cells and 
PE antibody), positive control for FITC (cells and FITC antibody), and positive control for 
APC (cells and APC antibody).  Each control tube (4 in total) had 100µl of HBSS+ solution, 
4µl of the cell suspension and 1µl of the relevant antibody. 
 
The main sample tube staining was achieved with the addition of 1µl per mouse of each of the 
4 antibodies (CD45-PE, Ter119-PE, Scar-1-FITC and PDGFRα-APC).  All samples were 
then incubated on ice in the dark for 30 minutes. 
 
Following incubation the control samples were washed by the addition of a further 1ml of 
HBSS+ solution.  The control samples were then spun at 2000rpm for 5 minutes.  The 
supernatant was discarded and the resulting cell pellets resuspended as described earlier.  The 
main sample conical tube was spun in a pre-chilled centrifuge at 4°C for 5 minutes at 280g 
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(1350 rpm).  Following this the supernatant was discarded and the resulting cell pellet 
resuspended.   
 
A solution of PI stain and HBSS was made with a concentration of 2µl of PI per ml of HBSS.  
The control tubes each had 500µl of PI/HBSS solution added.  The main sample had 1ml 
PI/HBSS solution per mouse added (10-15ml).  Each control tube was filtered into a new 
FACS cuvette through a sterile 35µm filter.  The main sample was filtered into multiple 
FACS cuvette tubes through a sterile 35µm filter aiming for 3-4ml in each cuvette.  All 
samples were then stored on ice in the dark ready for cell sorting. 
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2.4.6. Cell Sorting of PαS Mesenchymal Stem Cells 
A MoFloTM XDP (Beckman Coulter) Cell Sorter (Figure 1) was used for cell sorting.  The 
 
Figure 1 A photograph depicting the MoFlo
TM
 XDP Cell Sorter setup at the University of Birmingham 
 
cell sorter was configured to the manufacturer's exact specifications and calibrated 
extensively prior to use and the machine allowed to reach a stable working temperature.  
Whilst many lasers are available on this particular machine only the 488nm and 647nm lasers 
are used in this protocol.  Voltage, fanning, laser alignment and drop delay were all calibrated 
as per manufacturer specifications.  The negative control was run through to ensure detection 
of events without any significant detection by the lasers.  Following this each single antibody 
control/compensation tube was run starting with PE, then FITC then APC.  Each of these 
channels was compensated against the others in order to prevent significant colour bleed 
between the fluorescent antibodies.  Once compensation was complete gating was carried out.  
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Gating on PI allowed for the live cells to be selected.  Negative gates for PE and Terr119 were 
created and positive gates for PDGFRα and Sca-1 in order to select the PαS cells.  Finally a 
gate was drawn in order to select the central population of PαS cells based on previous 
optimisations and experience from the literature80,81.  The positively selected cells (PαS) were 
collected in a small collecting tube containing αMEM media with added PSG and 10% FCS.  
The mixture was then transferred into a FACS cuvette following completion of the sort and 
spun in a centrifuge at 2000rpm for 5 minutes.  The resulting pellet was resuspended and the 
appropriate amount of culture medium added for seeding onto 6 well plates. 
 
2.5. Growth Factor Priming of PαS Mesenchymal Stem Cells 
Growth factor priming of MSC has effects on differentiation and function.  In order to prepare 
PαS MSC primed with different growth factors freshly isolated PαS MSC were cultured either 
in standard medium (α-MEM + PSG + FCS), or standard medium with added growth factors.  
A concentration of 10ng/ml of Transforming Growth Factor β (TGF-β) was added to the 
standard medium and cells cultured as described earlier (2.1). 
 
2.6. OVA-Bil Mouse Model 
The OVA-Bil mouse model is a model of autoimmune liver disease where OVA Specific T-
Cells are directed at membrane bound ovalbumin expressed on apical sodium dependent bile 
acid transporters (ASBT) located on hepatocytes in a transgenic mouse.  This model was used 
to assess in vivo efficacy of the purified PαS MSC as described below. 
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2.6.1. Animal Husbandry 
The OVA-Bil mouse model, a model of Primary Biliary Cirrhosis, had been previously used 
by Dr Bertus Eksteen in our facility and frozen embryos were available, therefore the colony 
was re-derived from these.  The background mice used were C57BL/6 mice and 
heterozygotes for OVA-Bil were used and maintained.  Transgenic mice with the OT1 and 
OT2 ova-specific T-Cell phenotype were purchased from Jackson Laboratories and 
maintained at . 
 
All mice were housed in the  and cared for 
using the well established care protocols in that facility. 
 
All scientific procedures performed on animals were carried out in accordance with the 
Animals (Scientific Procedures) Act 1986, UK, and all procedures underwent ethical review 
prior to being performed. 
 
2.6.2. Induction of Liver Injury 
Male transgenic mice of both the OT1 (OVA-specific CD8+ T-Cells) and OT2 (OVA-specific 
CD4+ T-Cells) T-Cell receptor type were sacrificed using schedule 1 methods (cervical 
dislocation) aged between 8 and 12 weeks.  Splenectomy was performed immediately 
following confirmation of death.  Suspensions of splenocytes were created by passing the 
explanted spleens through a 70µm mesh.  Red cell lysis was performed using sterile water and 
the resulting suspension was washed and resuspended in PBS.  Cell counts were performed 
using a haemocytometer and suspensions were made with a cell count of 1x107 OT1 
splenocytes consisting of OVA-specific CD8+ T-Cells and 4x106 OT2 splenocytes consisting 
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of OVA-specific CD4+ T-Cells.  These were combined into single suspensions in a volume of 
200µl of PBS.  The splenocyte suspension was administered to 10 C57BL/6 OVA-Bil mice 
by intraperitoneal injection using a 25 gauge needle, each mouse receiving 1x107 OT1 cells 
and 4x106 OT2 cells in 200µl of PBS.   Blood samples were taken by cardiac puncture at days 
6-11 under terminal anaesthesia with isoflurane 2% and oxygen as the carrier gas, with 
.  Analysis of serum ALT and ALP was carried 
by the clinical biochemistry department at the Birmingham Women's Hospital.  Hepatectomy 
was performed immediately following confirmation of death and the liver samples were 
stored in liquid nitrogen.  This experiment was repeated 3 times to ensure consistency of 
results. 
 
2.6.3. Genotyping of OVA-Bil Mice 
OVA-Bil mouse genotyping was carried out in order to confirm carriage of the OVA 
transgene and therefore susceptibility to the OT1 and OT2 lymphocytes.  In order to control 
expression levels of ovalbumin within the liver it was decided that heterozygote male mice 
would be used. OT1 and OT2 mice were also genotyped in order to confirm expression of the 
ova-specific T-Cells.   A polymerase chain reaction (PCR) technique was used as described 
below. 
 
2.6.3.1. Sample Preparation 
Ear clippings were taken from mice at weaning by staff in the animal house using local 
protocols and were provided in labelled sample tubes which were immediately frozen for 
storage and subsequent analysis. 
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2.6.3.2. Polymerase Chain Reaction 
A hot start PCR technique was used which avoids the non-specific amplification of DNA at 
low temperatures due to the inactive nature of the Taq DNA polymerase enzyme and 
increases the yield of DNA. 
 
Tissue samples were mixed with 100µl of a 50 millimolar solution of Sodium Hydroxide and 
placed in a heating block at 95°C for 15 minutes.  Following heating samples were removed 
from the heating block an 10µl of a 1 Molar solution of 2-Amino-2-(hydroxymethyl)-1,3-
propanediol (TRIZMATM) base (Sigma-Aldrich) and mixed thoroughly. 
 
A master mix was created with a total volume of 18µl per mouse analysed.  The mixture 
contained 10µl of Qiagen Fast Cycling PCR master mix (Qiagen) which contains HotStarTaq 
polymerase, PCR buffer, Magnesium ions and deoxyribonucletide triphosphates (dNTP), 4µl 
of RNAase free water (Qiagen), 2µl of CoralLoad Dye (Qiagen), 1µl of Forward Primer 
(Qiagen) and 1µl of Reverse Primer (Qiagen).  New 200µl PCR eppendorfs were used and 
individually labelled.  18µl of the master mix described above was added followed by 2µl of 
digested mouse ears (processed DNA) was added.  Negative controls were used where the 
processed DNA was replaced with 2µl of water.  All tubes were briefly spun to ensure 
samples sat at the bottom of the tube. 
 
A G-storm GS1 PCR thermocycler (G-storm, UK) was used to process the samples.  An 
optimised protocol for hot start fast cycling was used based on a fragment length of 994 base 
pairs (Table 3).   
 
 
27 
 
Step Duration Temperature Notes 
Initial activation step 5 minute 95°C HotStarTaq and DNA 
Polymerase activated 
Denaturation 5 seconds 96°C  
Annealing 5 seconds 55°C 5°C below Tm of the 
primers 
Extension 30 seconds 68°C 3 seconds per base 
pair 
Repeat 35 cycles   
Final Extension 1 minute 72°C  
Holding As required 8°C Can be stored longer 
at -20°C if required 
Table 3 A Thermocycler protocol for HotStart PCR based on a base pair length of 994. This protocol was carried out on a 
G-Storm GS1 PCR thermocycler running for 35 cycles and 45 minutes. This was used in the HotStart PCR technique for the 
preparation of OVA-Bil DNA of gel electrophoresis. 
 
The protocol was run for 35 cycles taking approximately 45 minutes to complete.  Following 
completion the thermocycler stored the samples at 8°C as per protocol until required. 
 
2.6.3.3. PCR Gel Preparation 
A solution of 1.1% Agarose was made by dissolving 1.5g of agarose (Sigma-Aldrich) into 
75ml of Tris/Boric Acid/EDTA buffer (TBE, Sigma-Aldrich).  This was thoroughly mixed 
until all of the agarose had dissolved and then heated at high power using an 800w microwave 
for 80 seconds.  7.5µl of SYBR safe (Life technologies) was added to the agarose solution and 
mixed.  The mixture was then poured into a PCR setting block and a comb added to provide 
18 channels.  The solution was then left to cool form a gel (gelling point 36°C).  Once set the 
comb was removed and 750ml of TBE buffer poured carefully on top to ensure no bubbles 
were created as a running buffer. 
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2.6.3.4. PCR Gel Electrophoresis 
Following gel preparation the samples were added as follows.  The first well was designated 
as the ladder and 5µl of HyperLadderTM 100BP (Formerly HyperLadderTM IV, Bioline) and 
subsequent wells for the DNA samples, 10µl of which was added to each well.  The 
electrodes on the PCR block were attached to a regulated DC bench power supply with the 
anode connected to the end nearest to the sample wells and the cathode connected to the end 
furthest away.  The voltage is set to 100mV to start the sample separation.  The samples were 
run for 90 minutes in order to allow for adequate separation.  On completion the gel was 
viewed on an Ultra Violet transilluminator connected to a Personal Computer. 
 
2.6.4. Use of PαS Mesenchymal Stem Cells in OVA-Bil Model 
Purified PαS MSC were isolated as described previously.  Cells were cultured in α-MEM to 
passage 4-6.  Cytokine stimulation was carried out as described earlier.  Cells were 
trypsinised and then washed and resuspended in PBS.  Cell counting was performed and 
5x105 cells were suspended in a total volume of 200µl of PBS.  The cell suspension was 
infused into the tail vein of the OVA-Bil Mice on days 3 and 6 following induction of liver 
injury with OT1/OT2 OVA Specific T-Cells.  Control mice were infused with 200µl of PBS 
alone.  All mice were  on day 10 to enable analysis of serum ALT and ALP.  Blood 
samples were obtained by cardiac puncture following general anaesthesia with isoflurane.  
.  Hepatectomy was performed immediately 
following confirmation of death and the liver was placed in PBS ready for either fixing or 
further study. 
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2.6.5. Immunohistochemistry and Staining of Murine Solid Organs 
Solid organs were removed immediately following confirmation of death and placed in 
formalin for fixation.  Following fixation the organs were embedded in paraffin wax.  Paraffin 
blocks were sectioned when required into 4µm sections and secured to microscope slides 
ready for staining.  Haematoxylin and Eosin staining was carried out using local protocols by 
. 
  
 3.1. Cell sorting of PαS Mesenchymal Stem Cell
Extensive optimisation work had already been carri
technique as previously discussed.
between 10,000 and 12,000 cells per mouse, equ
for a 10 mouse isolation run.  The time taken to achieve this would be in the region of 10
hours.  Figure 2 shows an ideal P
looking at Sca-1 and PDGFR positive cells with the ideal gating location marked.  A yield of 
approximately 0.05% of the total number of events detected by the sorter would be expected.
 
Figure 2 Representative scatter plot
suspension. 10 male 10 week old C57BL/6 mice were used in this experiment and long bones extracted, finely chopped 
into a paste and digested with collagena
Sca-1, PDGFRα and a live dead marker. Live cells were gated A) and then the non
The final gate was set to isolate PDGFRα and Sca
approximately 0.05% of the total cell suspension.
 
This gating strategy also excluded 
well as dead cells which were stained with PI.
A. 
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3.2. Gel Electrophoresis of PCR of OVA
In order to confirm the genotype of the OVA
carried out on samples f
weaning.  In order to facilitate best use of the
it was decided that heterozygote males would be used in the OVA
Start PCR technique was used in 
and aiming to increase the DNA 
was familiar and the protocol already optimised by the manufacturer.  Example PCR gels 
following 90 minutes of electrophoresis
shown below (Figure 3). 
Figure 3 PCR genotyping of OVA-Bil and OT 1 
A) produce a band of 990bp size. Mice in lanes 8, 9 and 12 were
were all positive. OT-1 mice B) produce a band at 250bp and mice in lanes 5
OT-1 gene whereas lanes 1-4, 7 and 10 were all positive.
 
Mice with no OVA-Bil expression were .  Homozygotes were retained as breeding 
stock where needed 
 
A. 
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rom all offspring taken immediately following completion of 
 mouse colony and control ovalbumin expression 
-Bil experiments.  A Hot 
order to avoid low temperature non-
yield.  Minimal optimisation was required as the technique 
 at 100mV and transillumination on a UV camera are 
mice using a HotStart Taq polymerase and gel electrophoresis. OVA
 all negative for the OVA gene whereas 1
-6, 8-9 and 11-
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specific amplification 
 
-Bil mice 
-7, 10-11 and 13 
12 were all negative for the 
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3.3.   Liver Damage using the OVA-Bil Mouse Model 
The clinical importance of autoimmune hepatitis and PBC is described earlier.  The OVA-Bil 
model originally described in 200648, is a model in which transgenic mice expressing 
ovalbumin on apical sodium channels in the hepatobiliary system undergo induced 
hepatobiliary injury following inoculation with ova specific T lymphocytes.  This immune 
mediated biliary injury demonstrates features of the autoimmune condition PBC. 
 
Induction of liver injury was achieved by the intra-peritoneal administration of 1x107 OT1 
splenocytes consisting of OVA-specific CD8+ T-Cells and 4x106 OT2 splenocytes consisting 
of OVA-specific CD4+ T-Cells administered in a single suspension.  These cells will cause 
specific hepatobiliary injury due to the selective expression of ovalbumin in the recipient 
transgenic mice.  It was decided to use ALT and ALP as markers of liver damage as well as 
histological examination based on the literature and on the transferability to the clinical 
environment48.  These baseline experiments were repeated multiple times in order to quantify 
the degree of liver injury at various time points.  In keeping with the literature a consistent 
rise in both ALT and ALP from baseline levels was observed with a peak ALT at day 10 of 
635 IU/L and a peak ALP of 500 IU/L at day 11.  At day 11 the ALT levels began to fall in 
keeping with the literature.  On day 10 following adoptive transfer of OT1 and OT2 cells 
OVA-Bil mice were  and all solid organs removed and fixed in formalin for sectioning 
and histological analysis.  Following sectioning slides were prepared and stained with 
haematoxylin and eosin (H&E).  There were no significant findings in the solid organs apart 
from the liver, which is to be expected as the ovalbumin expression is specific to the 
hepatobiliary system and parallel experiments carried out by other group members confirmed 
that RNA expression of ovalbumin was limited to liver tissue.  Liver sections showed 
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lymphocytic infiltration throughout the biliary system with the greatest levels of infiltration 
effecting the biliary cells which encase the portal tracts (Figure 4). 
 
Figure 4 H&E Stained sections of liver tissue from injured OVA-Bil Mice at day 10 post adoptive transfer of 1x10
7
 OT1 
cells and 4x10
6
 OT2 cells demonstrating lymphocytic infiltration into the biliary cells encasing the portal tracts. 
Qualitative analysis was carried out on these sections. Male 8-12 week old OVA-Bil mice were injected IP with OT1 and 
OT2 cells and culled at day 10, Livers were removed, fixed in formalin and embedded in paraffin wax and 5µm sections 
were cut for staining. Sections from two different animals demonstrate 100x (A,C) and 200x (B,D) magnification. 
 
Interface hepatitis was also observed with clear spread of lymphocytes into the liver 
parenchyma.  Hepatocyte necrosis and apoptosis were also observed.  This pattern of injury 
clearly explains the concomitant ALT and ALP rises observed on serum testing. 
 
 
A. 
 
B. 
 
C. 
 
D. 
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3.4. Effect of PαS Cells on Injured and Uninjured Mice 
Parallel unpublished in vitro work carried out in the liver laboratories by Diarmaid Houlihan 
has shown that PαS MSC are able to suppress T-Cell proliferation.  Further unpublished 
parallel work has shown that cytokine priming increases the rate of growth of PαS MSC but 
without detrimental effect on their function.  It has also been shown that senescence is 
reduced without significant karyotypic transformation and no malignant gain of function.  
Because of this ongoing work and the parallel in vitro work carried out by Shankar Suresh 
which showed that T-Cell proliferation was suppressed more with cells cultured in TGF-βs 
than those cultured in α-MEM it was decided that PαS MSC cultured in TGF-β would be the 
best choice of cells to show a dampening down of the immunologic response in the OVA-Bil 
model.  It is clear from the literature and other work in our research group that the timing of 
the administration of MSC is crucial in order for them to have an immunosuppressive effect 
rather than the pro-inflammatory effect seen in some studies.  It was decided that PαS MSC 
should be administered on days 3 and 6 based on a review of the current literature and 
previous in vitro work.   
 
As this was a pilot investigation 3 control and 3 treatment mice were used.  A total of 5x105 
PαS MSC were administered via the tail vein, on day 3 and again on day 6 following 
induction of liver injury in OVA-Bil mice, and the mice  at day 10 to enable 
examination of ALT, ALP and liver histology. 
 
There was a fall in mean serum ALT and ALP levels following administration of PαS MSC.  
The decrease in ALT (Control ALT 1145 IU/L, PαS Treated ALT 523 IU/L) was more 
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marked than the decrease in ALP (Control ALP 203 IU/L, PαS Treated ALP 183 IU/L), 
however neither of these results reached statistical significance (Figure 5).  It should be noted 
however that there was a wide variation in serum ALT and ALP in the control group which 
will have affected the results. 
 
Figure 5 Serum ALT and ALP Levels Day 10 following adoptive transfer of 1x10
7
 OT1 cells and 4x10
6
 OT2 cells in OVA-Bil 
mice treated with PαS MSC demonstrate non-significant decreases. 3 control and 3 intervention male 8-12 week old 
OVA-Bil mice were injected IP with 1x10
7
 OT1 cells and 4x10
6
 OT2 cells. Treated mice were injected via the tail vein with 
5x10
5
 PαS MSC at day 3 and again at day 6 following adoptive transfer, control mice were given a PBS injection on the 
same days. Mice were culled at day 10 and serum samples sent for analysis. Student’s t-test was performed and did not 
demonstrate significance. 
 
Day 10 livers were removed and fixed in paraffin for staining as described previously.  
Histological analysis provided by Professor Stephen Hubscher demonstrated no difference in 
the number of lymphocytes infiltrating the hepatobiliary system with similar numbers found 
in both liver parenchyma and in the portal architecture (Figure 6).    
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Figure 6 Liver histology of treated and untreated OVA-Bil livers day 10 post adoptive transfer of 1x10
7
 OT1 cells and 4x10
6
 
OT2 cells demonstrating no difference in lymphocytic infiltration in the portal regions. Qualitative analysis was carried 
out on these sections. Male 8-12 week old OVA-Bil mice were injected IP with 1x10
7
 OT1 cells and 4x10
6
 OT2 cells.  A) 
Treated mice were injected via the tail vein with 5x10
5
 PαS MSC at day 3 and again at day 6 following adoptive transfer, 
B) control mice were given a PBS injection on the same days. Mice were culled at day 10, Livers were removed, fixed in 
formalin and embedded in paraffin wax and 5µm sections were cut for staining. 
 
Whilst this analysis was quantitative it did not take into account the relative size differences in 
mouse livers and further work would be needed in order to determine if there is a true 
difference. 
 
  
A. 
 
B. 
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4. DISCUSSION 
The isolation of purified PαS MSC is a complex technique initially described by Morikawa80, 
and further refined by Houlihan81.  This technique has proven difficult to replicate meaning 
that the mouse MSC literature is still very much based on the use of plastic adherent MSC, a 
more heterogeneous population of cells, or the use of human MSC administered to mice.  A 
large part of the focus of this research has been on the mastery of the technique of prospective 
isolation of highly purified PαS MSC using novel cell markers to identify and sort them.  This 
has then created the environment to enable pilot in vivo work to show potential efficacy of 
these cells. 
 
4.1. Limitations of the Experimental Techniques 
Isolation of PαS MSC is a rewarding but timely process.  Whilst the accuracy and 
reproducibility of this technique is good, the low cell yield requires that cells be culture 
expanded in order to produce enough cells exert an effect.  Whilst it has not been fully 
elucidated what the correct dose or route of administration may be, it is clear that a much 
greater number is required than can be achieved at early passage with this technique.  The 
benefit of using a purified population of cells which have no contaminating haematopoietic or 
fibroblastic cell types outweighs the difficulties encountered.  Culture expansion could be 
potentially be improved by growth factor supplementation but this would require further study 
in order to demonstrate safety and efficacy. 
 
This study was designed as a pilot study in order to demonstrate the feasibility of 
prospectively isolating PαS MSC and administering them in a mouse model of autoimmune 
liver disease.  It is therefore not surprising that the results found are not significant as the 
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study was not powered to achieve significance, although encouraging that a non-significant 
reduction in markers of liver injury has been demonstrated.  Further study is required with 
increased numbers of animals in order to ascertain if there is a true effect present. 
 
The choice of ALT as a marker for liver injury is backed up by the literature and by the 
clinical correlation in humans.  In retrospect the choice of ALP is perhaps less wise.  Whilst 
changes in ALP were seen this is likely related to the different age of mice as in C57BL/6 
mice there is limited expression in the liver and therefore serum levels are influenced much 
more by bone turnover which will increase serum ALP and is greater in younger mice. 
 
The assessment of liver histological sections did not yield a significant difference, however 
this was a qualitative assessment only.  Quantitative assessments may yield a different result.  
Whilst there may not be a visible overall difference in the infiltrative cells demonstrated 
specific staining for immune cells using CD45 or F4/80 should be carried out along with 
quantitative analysis in order to look at more specific markers of immune cell infiltration.  
Flow cytometric analysis of liver cell digest would also yield more specific information 
regarding the immune cell infiltration. 
 
4.2. Purified PαS Mesenchymal Stem Cells 
The MSC literature is littered with contrasting studies and a lack of clarity regarding the 
mechanisms of action of MSC, mainly because as yet this has not been fully elucidated.  
Concerns have been raised regarding the need to grow in culture what is a very rare 
population of cells for a prolonged period of time in order obtain the large numbers required 
for therapy, and the inherent risks of DNA copying abnormalities and tumour formation82.  
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These concerns have also been raised when considering murine MSC83.  The cell populations 
considered here are heterogeneous and it cannot be clear exactly what make up of cells there 
are as the current definition of an MSC and its accompanying cell surface markers are still not 
specific enough to yield a purified population.  Prior to the development of a prospective 
isolation technique MSC were isolated based on their plastic adherence properties which led 
to a heterogeneous population of cells with contamination from haematopoietic cells and 
various fibroblastic cells making it very difficult to study mechanistic properties of MSC.  A 
key advantage of the isolation technique described in this study is that it reliably produces a 
highly purified set of cells with a unique combination of surface markers, namely PDGFRα 
and Sca-1, so called PαS cells.  The amount of clonal expansion required will also be 
significantly less with a purified cell population therefore reducing the risk of malignant 
transformation.  Further work is required to confirm the karyotypic stability of PαS MSC.  It 
will be important to use sensitive techniques for assessing for genetic stability as it has been 
shown that traditional techniques such as G-banding analysis of metaphase chromosomes is 
not adequate to pick up abnormalities in MSC and more advanced techniques such as array 
comparative genomic hybridization (aCGH) are required84.  Assessment of tumour formation 
following multiple in vivo infusions would also be useful in assessing the relative safety of 
PαS MSC. 
 
4.3. OVA-Bil Mouse Model of Autoimmune Liver Disease 
The OVA-Bil mouse model used in the experiments in this study requires the adoptive 
transfer of CD4+ and CD8+ T-Cells specific for ovalbumin by modified OVA-Bil mice who 
express ovalbumin on the apical sodium channel of their biliary epithelium.  This leads to a 
bile duct specific injury pattern and an associated injury to the surrounding hepatocytes48.  
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The baseline liver injury seen in the mice injured in this study showed a 25-30 fold increase in 
serum ALT from the uninjured controls at day 10, but only a doubling in ALP levels 
following adoptive transfer of 1x107 OT1 cells and 4x106 OT2 cells.  Whilst it is possible that 
the PBS carrier could have an effect on serum markers of liver injury, this is not a recognised 
phenomenon and the use of the same volume of PBS in the control and treated groups in this 
study will mitigate any effect that may have occurred due to carrier use.  Lymphocytic 
infiltration particularly around the bile ducts was also seen on histology.  This is entirely 
consistent with the results found in the original description of the OVA-Bil model by 
Buxbaum et al48.  The histological findings of interface hepatitis and leakage of lymphocytes 
into the surrounding liver parenchyma were also consistent with the findings of Buxbaum.  
Due to the amount of necrosis seen in these areas it is likely that the release of cellular 
contents will further drive the immune system to damage hepatocytes and lead to hepatocyte 
apoptosis85.  As in other models of liver disease such as the MDR2-/-86, leakage of bile acid 
and cholestasis will further contribute to hepatocyte necrosis and liver injury.  In particular, 
the presence of CD8+ T-Cells within the hepatic parenchyma can lead to hepatic 
inflammation due to the release of TNF-α and IFNγ by the T-Cells87.  Targeting T-Cells 
would therefore be a potential therapeutic strategy in these types of liver injury.  The key 
advantages of the OVA-Bil model of liver injury used are its clear T-Cell mediated injury 
pattern which is not as well defined in other models and the ability to induce liver injury at a 
convenient time rather than using a spontaneous model. 
 
4.4. Mesenchymal Stem Cells In Autoimmune Disease 
Autoimmune disease is an important clinical entity as whilst it is not the most common of 
diseases encountered, a lot of autoimmune disease has limited treatment options.  Treatments 
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that do exist often involve either long courses of corticosteroids with the accompanying side 
effects (Table 4), or immunosuppressant drugs with risk of infection and a dose and duration 
related risk of renal failure. 
 
 
Side Effects 
Weight Gain Hypertension 
Osteoporosis Glaucoma 
Cushing's Syndrome Cataracts 
Proximal Muscle Wasting Delayed Wound Healing 
Steroid Induced Diabetes Susceptibility to Infection 
Growth Retardation in Children Depression 
Steroid Psychosis Insomnia 
Table 4 A summary of the common side effects seen in patients taking regular corticosteroids 
 
Autoimmune liver diseases are a group of conditions that fit the above description with the 
caveat that liver transplant remains an option for late stage disease.  Unfortunately the demand 
for donor organs is far outstripped by the number of patients on the transplant waiting list 
with just over half of patients who need a liver transplant actually receiving one2. MSC 
appear to be an attractive option to treat autoimmune liver disease due to their ability to 
modulate the immune system whilst preserving the response to infection88, as well as avoiding 
the side effects mentioned above. The pilot in vivo work in this study showed no significant 
difference in OVA-Bil mice with induced liver injury following adoptive transfer of OT1 and 
OT2 splenocytes at day 10 post injury either with or without treatment with 5x106 PαS MSC 
at day 3 and 6 when comparing ALT, ALP and liver histology.  It is worth noting however, 
42 
 
that there was a definite trend showing a reduction in ALT in the mice treated with PαS MSC 
when compared with the mice that did not undergo treatment.  This is encouraging and further 
study with larger numbers of mice is required in order to achieve a definite answer as a clear 
limitation of this series of experiment is the low numbers of mice used in order to generate the 
pilot data. Timing of infusions of MSC is also key and their immune regulating properties as 
has been shown in models of kidney transplant89, where early administration led to an 
immunosuppressive actions, but later administration led to a pro-inflammatory effect and 
early graft dysfunction.  Understanding this ability to have both pro and anti-inflammatory 
effects may yield a greater understanding of how MSC exert their effects and could lead to 
improving their therapeutic potential.  Further work modifying the timings of MSC infusions 
may yield more significant results in the OVA-Bil model of autoimmune disease, as the 
current timings were decided upon based on a review of the literature, but as no studies using 
these highly purified cells have been carried out in autoimmune liver disease, there is room 
for refinement. 
 
4.5. Mechanisms Of Mesenchymal Stem Cell Immunosuppression 
A large number of possible mechanisms by which MSC interact with the immune system and 
exert their effect have been suggested, the main route by which MSC are thought to work is 
by cell to cell contact and the secretion of anti-inflammatory cytokines local to the area of 
inflammation (Table 5). 
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Cytokine Levels Altered By Mesenchymal Stem Cells 
HO1 IDO  
TGF-β PGE2 
IL-10 HLAG5 
IL-6 Reduce IL-12 
IL-4 Reduce TNF 
HGF Reduce IFNγ 
Table 5 A summary of the inflammatory cytokines modulated by MSC 
 
A key mechanism in MSC induced immunosuppression is due to their effects on T 
Lymphocytes90,91 and parallel work in the Newsome Laboratory in our group has confirmed 
this in vitro.  Whilst the lymphocytic infiltration was analysed using histological sections in 
this study no account was made for the relative sizes of the livers and so a more quantitative 
measure may yield different results.  Lymphocyte isolation from hepatic tissue and 
lymphocyte counting using flow cytometry with markers specific to CD4 and CD8 would 
give a more accurate indication of the relative amounts of lymphocytes when correct for size 
of organ and may show an improved effect in the MSC treated group. 
 
The effect of MSC on infiltrating lymphocytes in the hepatic parenchyma is likely to be key 
and will require further study to ascertain the significance of this.  The OVA-Bil model used 
in this experiment involves the adoptive transfer of exogenous lymphocytes targeted 
specifically at ovalbumin.  In order to quantify the amount of liver injury cause by the OVA-
Bil mouse's own lymphocytes following stimulation from hepatic necrosis the next step would 
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be to used tagged OT1 and OT2 cells with, for example Green Fluorescent Protein (GFP) in 
order to distinguish the relative contributions to the hepatitis seen.   
 
It is still not clear whether MSC only exert a direct effect on immune cells such as T 
Lymphocytes or whether they have effects on other immune cells.  MSC have been shown to 
exert an immunosuppressive effect on Dendritic Cells92, B Cells93 and natural killer cells94.  
MSC can inhibit the differentiation of dendritic cells, in particular the differentiation from 
monocytes to immature dendritic cells, a cytokine mediated process.  This inhibition not only 
prevents the expression of dendritic cell surface markers but also leads to a functional 
inhibition of dendritic cell cytokine release, in particular the inhibition of IL-12 release, a 
potent stimulator of T-Cells94.  This could represent a mechanism by which MSC exert their 
effect on T-Cell stimulation.  Further study into the mechanisms behind this process and the 
relative contribution to MSC mediated immunosuppression are needed.  One such experiment 
could be to knock out macrophages using clodronate, to compare the immunosuppressive 
effect in the absence of this pathway. 
 
4.6. Localisation of Mesenchymal Stem Cells During Immunosuppression 
The current accepted position in the literature is that MSC need to access an area of 
inflammation in order to exert their immunosuppressive effect95, although increasingly there 
is evidence that a systemic effect may also play a role96.  In this study systemically 
administered MSC have a local effect on liver inflammation, reducing the amount of 
hepatocyte damage as demonstrated by serum ALT levels, however it is not clear from these 
experiment whether the MSC were acting systemically, locally or a combination of the two.  
Further work needs to be carried out to show, not only where MSC migrate in models of 
 Figure 7 Demonstration images using CryoViz
organ specific views (Provided by BioInVision)
inflammation, but also more importantly where they are functionally immunosuppressive.  
The use of labelled MSC with GFP in models of inflammation would address the first part of 
this question.  Novel imaging techniques such as CryoViz
resolution (single cell level) image 
infusion of MSC (Figure 7)
In order to address the question of where MSC exert their functional suppression it would be 
necessary to look at markers of MSC suppressive activity.  One marker that has been found to 
be key in MSC induced immunosuppression is IDO and work in the Newsome lab
far unpublished has confirmed this.  Using an RNA knockdown technique such as lentiviral 
transfection, markers such as IDO could be tagged with a fluorescent protein which woul
expressed on translation of the RNA linked to IDO, therefore allowing tracking of 
functionally active MSC rather than all MSC.  This could be carried out for 
for MSC related immunosuppression to give a rounded picture of what is expre
where during models of inflammatory diseases.
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It has recently been shown that MSC can exert a completely distant immunosuppressive effect 
without migrating to areas of active inflammation.  This effect has been shown to be superior 
when encapsulated MSC are injected subcutaneously into mouse models of autoimmune liver 
disease and graft versus host disease72, when compared with IV administration.  So far this is 
the only study to suggest that MSC may have an immunosuppressive effect when 
encapsulated.  The importance of further work looking at encapsulated MSC is twofold; from 
a mechanistic standpoint it enables further study into the remote effects of MSC by preventing 
the local effects due to the cells being trapped, secondly encapsulated cells survive longer 
than cells infused IV and may have a longer and more substantial effect72. 
 
4.7. Future Uses of Mesenchymal Stem Cells 
This study has focussed on the use of MSC in models of autoimmune liver disease, the aim 
being to provide a novel treatment strategy that reduced the amount of immunosuppressant 
drugs required and their accompanying complications, and also to aim to reduce the number 
of patients going on to develop end stage liver disease and ultimately require a liver 
transplant.  There is however another use that could be considered for MSC and that is to 
improve outcomes from liver transplant itself.  Whilst a lot of liver diseases are treatable it is 
inevitable that some either do not respond to therapy, or there is no curative therapy other than 
liver transplantation for example PSC.  Donor livers undergo an ischaemic insult prior to 
transplantation.  This ischaemic injury is more profound in the Donation after Cardiac Death 
(DCD) when compared with Donation after Brainstem Death (DBD)98, as there is usually a 
much longer warm ischaemia time due to the nature of the dying process.  There is a 
considerable contribution to the resultant damage to the liver by the immune system which is 
functionally connected to the ischaemia reperfusion injury seen, each one mutually 
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reinforcing the other99.  The immune mediated damage seen in explanted livers is a candidate 
for MSC therapy, but the efficacy and timing of this will require considerable further study.  
There may also be a role for MSC in acute and chronic rejection, another T-Cell mediated 
non-suppurative cholangitis100.  Further work looking into efficacy of MSC in models of liver 
transplantation may yield interesting and useful opportunities for clinical translation. 
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5. CONCLUSIONS 
The aims of this study were to acquire the ability to isolate purified MSC in a reproducible 
manner which was achieved, and to test the ability of MSC to suppress autoimmune mediated 
damage in a model of autoimmune hepatitis, which was partially achieved.  This study was a 
pilot study and has demonstrated feasibility in carrying out the described techniques. The 
burden of end stage liver disease remains great and novel therapeutic strategies are required.  
Mesenchymal stem cells may have a role to play in the treatment of diseases due to 
autoimmunity and further study into both the efficacy and mechanism of action of these cells 
is required.  
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